Jyong Biotech Stock (NASDAQ:MENS)
Previous Close
$1.47
52W Range
$1.43 - $67.00
50D Avg
$7.61
200D Avg
$28.29
Market Cap
$117.84M
Avg Vol (3M)
$896.33K
Beta
6.19
Div Yield
-
MENS Company Profile
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages
MENS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| TVTX | Travere Therapeutics, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |
| CELC | Celcuity Inc. |
| CGON | CG Oncology, Inc. Common stock |
| XENE | Xenon Pharmaceuticals Inc. |
| DYN | Dyne Therapeutics, Inc. |
| LEGN | Legend Biotech Corporation |
| CNTA | Centessa Pharmaceuticals plc |
| APGE | Apogee Therapeutics, Inc. |